News

Zenas sees results from obexelimab Phase 3 trial near year-end

Zenas Biopharma said it expects top-line results from INDIGO, a Phase 3 clinical trial testing obexelimab in people with immunoglobulin G4-related disease (IgG4-RD), “around year-end.” We are very pleased with the rapid advancement of our broad obexelimab development program,” Lonnie Moulder, founder and CEO of Zenas, said…

Salivary gland imaging can make it easier to diagnose IgG4-RD

Imaging of the salivary glands can help distinguish IgG4-related disease (IgG4-RD) from other disorders that can cause inflammation in those glands, a new study shows. The findings indicate people with salivary gland inflammation related to IgG4-RD tend to show distinctive patterns of damage to some of the tubes, or…

IgG4 levels shape autoimmune pancreatitis, study finds

Type 1 autoimmune pancreatitis (AIP), a type of IgG4-related disease (IgG4-RD) involving the pancreas, can look different depending on the levels of immunoglobulin G4 (IgG4), a study found. People with normal IgG4 levels typically had more limited damage in the pancreas and some issues outside it, the researchers found.

Brain, eye changes are common IgG4-RD neurological problems

Eye problems, inflammation in the brain’s pituitary gland, and thickening of the membranes around the brain and spinal cord are the most common neurological complications seen with immunoglobulin G4-related disease (IgG4-RD), a review study reports. Neurological problems in IgG4-RD can usually be managed with standard treatments, though researchers emphasized…

High IgG4 antibody blood levels ID 75% of IgG4-RD cases: Study

High blood levels of IgG4 antibodies may be a sign of many diseases, not solely IgG4-related disease (IgG4-RD), but blood tests for IgG4 can identify most IgG-RD cases and rule it out for most people without the disease, a study in Spain reports. Certain respiratory conditions, autoimmune diseases, and…

Immune cell ratio may predict IgG4-RD relapse risk: Study

A ratio of different types of immune cells called the eosinophil-to-lymphocyte ratio (ELR) may predict risk of relapse in people with immunoglobulin G4-related disease (IgG4-RD), according to a long-term study. People with IgG4-RD had higher ELRs than those with other inflammatory diseases, and a higher ELR was associated with…

Subset of immune T-cells may be therapeutic target in IgG4-RD

A specific subset of immune cells known as gamma-delta 2 T-cells plays a key role in the development of immunoglobulin G4-related disease (IgG4-RD), a study reports. Particularly, these cells were found to acquire an immune profile, called T helper 2 (Th2)-like phenotype, to strongly promote the formation of plasma…